as 02-21-2025 4:00pm EST
Founded: | 2000 | Country: | United States |
Employees: | N/A | City: | NORCROSS |
Market Cap: | N/A | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 258.9K |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.73 | EPS Growth: | N/A |
52 Week Low/High: | $0.73 - $4.27 | Next Earning Date: | 03-28-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Shlevin Harold H. | GALT | Director | Dec 30 '24 | Buy | $1.16 | 6,500 | $7,540.00 | 15,206 | |
FREEMAN KEVIN D | GALT | Director | Dec 24 '24 | Buy | $0.81 | 10,000 | $8,134.00 | 44,769 | |
ELDRED KARY | GALT | Director | Dec 24 '24 | Buy | $0.82 | 13,469 | $11,044.58 | 63,682 | |
Zordani Richard A. Jr. | GALT | Director | Dec 24 '24 | Buy | $0.82 | 10,000 | $8,164.00 | 42,083 | |
LEWIS JOEL | GALT | President and CEO | Dec 23 '24 | Sell | $0.89 | 56,000 | $49,610.40 | 897,012 | |
CALLICUTT JACK W | GALT | Chief Financial Officer | Dec 23 '24 | Sell | $0.89 | 40,000 | $35,492.00 | 7,614 | |
Jamil Khurram | GALT | Chief Medical Officer | Dec 23 '24 | Sell | $0.88 | 13,654 | $12,044.19 | 26,346 |
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Argus Research
a month ago
Argus Research
a month ago
Argus Research
a month ago
Argus Research
a month ago
Argus Research
a month ago
GlobeNewswire
a month ago
Argus Research
a month ago
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.